Literature DB >> 23649413

Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey.

Paul Arora1, Priya Vasa, Darren Brenner, Karl Iglar, Phil McFarlane, Howard Morrison, Alaa Badawi.   

Abstract

BACKGROUND: Chronic kidney disease is an important risk factor for death and cardiovascular-related morbidity, but estimates to date of its prevalence in Canada have generally been extrapolated from the prevalence of end-stage renal disease. We used direct measures of kidney function collected from a nationally representative survey population to estimate the prevalence of chronic kidney disease among Canadian adults.
METHODS: We examined data for 3689 adult participants of cycle 1 of the Canadian Health Measures Survey (2007-2009) for the presence of chronic kidney disease. We also calculated the age-standardized prevalence of cardiovascular risk factors by chronic kidney disease group. We cross-tabulated the estimated glomerular filtration rate (eGFR) with albuminuria status.
RESULTS: The prevalence of chronic kidney disease during the period 2007-2009 was 12.5%, representing about 3 million Canadian adults. The estimated prevalence of stage 3-5 disease was 3.1% (0.73 million adults) and albuminuria 10.3% (2.4 million adults). The prevalence of diabetes, hypertension and hypertriglyceridemia were all significantly higher among adults with chronic kidney disease than among those without it. The prevalence of albuminuria was high, even among those whose eGFR was 90 mL/min per 1.73 m(2) or greater (10.1%) and those without diabetes or hypertension (9.3%). Awareness of kidney dysfunction among adults with stage 3-5 chronic kidney disease was low (12.0%).
INTERPRETATION: The prevalence of kidney dysfunction was substantial in the survey population, including individuals without hypertension or diabetes, conditions most likely to prompt screening for kidney dysfunction. These findings highlight the potential for missed opportunities for early intervention and secondary prevention of chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23649413      PMCID: PMC3680588          DOI: 10.1503/cmaj.120833

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  24 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Canadian Health Measures Survey: sampling strategy overview.

Authors:  Suzelle Giroux
Journal:  Health Rep       Date:  2007       Impact factor: 4.796

3.  Canadian Health Measures Survey: rationale, background and overview.

Authors:  Mark Tremblay; Michael Wolfson; Sarah Connor Gorber
Journal:  Health Rep       Date:  2007       Impact factor: 4.796

4.  Canadian Health Measures Survey: clinic operations and logistics.

Authors:  Shirley Bryan; Marc St-Denis; Dana Wojtas
Journal:  Health Rep       Date:  2007       Impact factor: 4.796

Review 5.  The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.

Authors:  Laura Chalmers; Fredrick J Kaskel; Oluwatoyin Bamgbola
Journal:  Adv Chronic Kidney Dis       Date:  2006-10       Impact factor: 3.620

6.  Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.

Authors:  Amit X Garg; Bryce A Kiberd; William F Clark; R Brian Haynes; Catherine M Clase
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

7.  Prevalence of chronic kidney disease in the United States.

Authors:  Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

8.  Predictors of new-onset kidney disease in a community-based population.

Authors:  Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy
Journal:  JAMA       Date:  2004-02-18       Impact factor: 56.272

9.  Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes.

Authors:  Meredith C Foster; Shih-Jen Hwang; Martin G Larson; Nisha I Parikh; James B Meigs; Ramachandran S Vasan; Thomas J Wang; Daniel Levy; Caroline S Fox
Journal:  Arch Intern Med       Date:  2007-07-09

Review 10.  Prevalence of chronic kidney disease in population-based studies: systematic review.

Authors:  Qiu-Li Zhang; Dietrich Rothenbacher
Journal:  BMC Public Health       Date:  2008-04-11       Impact factor: 3.295

View more
  138 in total

1.  Online clinical pathway for managing adults with chronic kidney disease.

Authors:  Craig Curtis; Carlee Balint; Yazid N Al Hamarneh; Maoliosa Donald; Ross T Tsuyuki; Kerry McBrien; Wes Jackson; Brenda Hemmelgarn
Journal:  Can Pharm J (Ott)       Date:  2015-09

2.  Community pharmacist targeted screening for chronic kidney disease.

Authors:  Yazid N Al Hamarneh; Brenda Hemmelgarn; Craig Curtis; Carlee Balint; Charlotte A Jones; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2016-01

3.  Computed tomography identified factors that preclude living kidney donation.

Authors:  Katerina Mastrocostas; Christina M Chingkoe; Kenneth T Pace; Joseph J Barfett; Anish Kirpalani; Gevork N Mnatzakanian; Paraskevi A Vlachou; Errol Colak
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

Review 4.  Obstructive Sleep Apnea and Kidney Disease: A Potential Bidirectional Relationship?

Authors:  Bisher Abuyassin; Kumar Sharma; Najib T Ayas; Ismail Laher
Journal:  J Clin Sleep Med       Date:  2015-08-15       Impact factor: 4.062

5. 

Authors:  Laurie-Anne Nguyen
Journal:  Can Fam Physician       Date:  2019-08       Impact factor: 3.275

6.  Draw me your disease: Obstacles to palliative intervention for patients with noncancer diagnoses.

Authors:  Laurie-Anne Nguyen
Journal:  Can Fam Physician       Date:  2019-08       Impact factor: 3.275

Review 7.  Approach to the detection and management of chronic kidney disease: What primary care providers need to know.

Authors:  Allan K Grill; Scott Brimble
Journal:  Can Fam Physician       Date:  2018-10       Impact factor: 3.275

8.  Evaluation of a mentorship program to support chronic kidney disease care.

Authors:  Jocelyn Pang; Allan Grill; Monisha Bhatt; Graham L Woodward; Scott Brimble
Journal:  Can Fam Physician       Date:  2016-08       Impact factor: 3.275

9.  The See Kidney Disease Targeted Screening Program for CKD.

Authors:  Lauren E Galbraith; Paul E Ronksley; Lianne J Barnieh; Joanne Kappel; Braden J Manns; Susan M Samuel; Min Jun; Rob Weaver; Nadine Valk; Brenda R Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

10.  Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.

Authors:  Laurence Lepage; Anne-Claude Dufour; Jessica Doiron; Katia Handfield; Katherine Desforges; Robert Bell; Michel Vallée; Michel Savoie; Sylvie Perreault; Louis-Philippe Laurin; Vincent Pichette; Jean-Philippe Lafrance
Journal:  Clin J Am Soc Nephrol       Date:  2015-11-17       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.